Global Alliance for TB Drug Development

With a budget of over half a billion dollars, Johnson & Johnson has outlined its ambitious strategy to collaborate with public and private partners to accelerate efforts to eliminate HIV and tubercu

As the US Food and Drug Administration continues to finalize its guidance on the limited population antibacterial drug (LPAD) pathway, it will have to do so without its lead antimicrobial czar Ed Cox,

Here's your news in brief: It was by far the US Food and Drug Administration's busiest week of the year for novel drug approvals with five such products getting the green light from the agency: Genen

The US Food and Drug Administration showed off its willingness to allow for regulatory flexibility in in certain clinical development programs with its approval of the Global Alliance for TB Drug Dev